I'll research C.H. Robinson (CHRW) before writing the preview. Let me gather recent earnings, filings, news, and price data.Significant news — a $604M jury verdict. Let me dig into the recent earnings call, the 8-K, and price action.I have strong material. Let me pull exact Q1 financials and check on the Montgomery Supreme Court case and Q2 consensus.Let me quickly check the Montgomery Supreme Court case status and Q2 consensus, plus grab the prior-year Q2 2025 comps.I now have everything I need. Here's the earnings preview.

C.H. Robinson (CHRW) — Q2 FY2026 Earnings Preview

Reports after the close Wednesday, July 29, 2026 (2026Q2 Earnings Call)

The setup: a great operating story colliding with a fresh legal shock

Six days before this print, the investment case changed. On July 23, 2026, a Dallas County, Texas jury returned an advisory verdict of $604 million in compensatory damages against C.H. Robinson (and two co-defendants) tied to a trucking accident involving an independent motor carrier. Per the company's 8-K, the verdict "remains subject to post-trial proceedings," the company "disagrees" with it, and it "expects to appeal if the jury's verdict is entered as final."

This did not happen in a vacuum. On May 14, 2026, the U.S. Supreme Court ruled unanimously (in Montgomery v. Caribe Transport II) that the FAAAA does not preempt state-law negligent-selection/hiring claims against freight brokers — the exact opposite of what management confidently predicted on the Q1 call ("The Montgomery case is a case that we expect to win…we've won in the Seventh Circuit…we expect that we'll win this in the Supreme Court as well"). The Dallas verdict is the first high-profile jury outcome under this new liability regime, so investors will read it as a template for what broadened broker liability can cost.

The market reaction has been severe and fast:

Date	Close	Note
Jul 21	$209.42	Recent high
Jul 23	$205.51	Verdict announced after this session
Jul 24	$186.51	‑9.3%
Jul 27	$174.46
Jul 28	$169.37	~‑18% vs. pre-verdict

That ~18% three-day drawdown erased most of what had been a spectacular run (the stock was up roughly 97% over the trailing 52 weeks and ~19% YTD heading into the verdict). The tension going into the print: CHRW's underlying execution has been excellent, but a new, hard-to-quantify legal tail risk now sits on top of it.

What the Street expects for Q2

Consensus adjusted EPS ≈ $1.49, up ~15.5% vs. the $1.29 adjusted EPS a year ago (Q2 2025 GAAP diluted was $1.26).
Full-year 2026 consensus ≈ $6.08, vs. the company's reaffirmed Investor Day target of ~$6.00 EPS assuming no market growth.
CHRW has beaten EPS estimates in each of the last four quarters, so the bar is not high on operations — the risk is qualitative (litigation) rather than the number itself.

Prior-year Q2 2025 comps to anchor against: - Revenue $4.14B; adjusted gross profit $693.2M; income from operations $215.9M (+21.2% YoY); adjusted operating margin 31.1%. - NAST: adjusted gross profit $432.2M, op income $164.0M, adjusted op margin 37.9%. - Global Forwarding: adjusted gross profit $187.6M, op income $51.3M.

Note Q2 is seasonally the strongest quarter (produce season, food & beverage). Management flagged the 10-year average Cass sequential move is +4.5% into Q2.

The operating debate: can NAST hold margins in a tightening truckload market?

This is the core fundamental question. The North American truckload market has entered a supply-driven tightening — spot rates rose sharply through 1H26, and management raised its full-year dry-van spot rate assumption to +17% (from +8% three months earlier).

Historically, rising spot rates squeeze brokers whose contractual rates are locked. In Q1 2026, CHRW navigated this impressively: - NAST gross margin held flat at 14.6% despite truckload spot costs up ~19% YoY, via targeted contract repricing, capturing higher-margin transactional/spot volume as route guides failed, and widening its cost-of-hire advantage. - NAST adjusted operating margin ex-restructuring expanded 310 bps to 37.4%. - Total NAST volume was flat vs. a Cass Index down 6.2% — the 12th consecutive quarter of share gains. - Company adjusted EPS grew 15.4% to $1.35.

What to watch in Q2: 1. NAST gross margin trajectory — can they again defend ~14.6% as spot rates stay elevated? Management said repricing tools now let them react within days rather than a full quarter. 2. Fuel headwind to margin % — management warned that a rising fuel surcharge mechanically compresses reported truckload gross margin % (no dollar impact); this could persist into Q2. 3. Volume vs. margin mix — management has repeatedly said it "takes the volume it wants," prioritizing gross profit per load over share. Watch whether an improving demand backdrop shifts them back toward volume growth. 4. Contract vs. transactional mix — jumped from ~65% to ~70% contractual in Q1; management expects this to "equalize" over time.

Segments and self-help

Global Forwarding remains the soft spot. Q1 revenue fell 14.2% and op income fell 26.2% on lower ocean volumes and rates (excess vessel capacity, tariff/geopolitical disruption). Watch for the promised Lean AI/productivity playbook to "kick in" here in 2H26.
Cost/productivity engine. Average headcount was down ~12% YoY in Q1; management targets double-digit productivity in both NAST and Global Forwarding in 2026, over-indexed to the second half. 2026 guides: personnel expense $1.25–1.35B, SG&A $540–590M, capex $75–85M, tax rate 18–20%.
Capital returns / balance sheet. CHRW returned $359.8M to shareholders in Q1 ($280.7M buybacks + $79.0M dividends), more than double the prior year, with net debt/EBITDA at 1.32x and ~$1.24B liquidity. A key question is whether the litigation overhang causes any pause in the aggressive buyback pace.

Key things to listen for on the call

The $604M verdict — accounting and messaging. Will CHRW book a reserve/accrual, and how large? What is its insurance coverage on contingent auto liability? What's the appeal timeline, and does it change the range of ultimate exposure? Management will likely stress the "advisory" nature and pending post-trial motions.
Broader Montgomery implications. Post-SCOTUS, brokers face negligent-selection liability nationwide. Watch for commentary on carrier-vetting/safety process changes, rising insurance costs across the industry, and whether CHRW argues its scale/financial strength is a competitive advantage if smaller brokers get squeezed out (a point Bozeman hinted at in Q1: "there's going to be some insurance implications…that's going to impact different people in different ways").
Guidance. Does the ~$6.00 EPS target hold? With spot rates running well above plan and self-help intact, the operating outlook may actually be fine — but any litigation reserve could hit GAAP EPS.
The disconnect to exploit. With the stock down ~18%, the read-through is whether the market is overpricing a single, appealable, advisory verdict versus a genuine step-change in the industry's cost of doing business.

Bottom line

Operationally, CHRW enters Q2 with strong momentum — Street looks for ~$1.49 adjusted EPS (+~15%), continued NAST share gains and margin defense in a tightening truckload market, and an intact Lean AI/productivity story. But the print is now overshadowed by a new, genuinely uncertain legal risk: the post-Montgomery liability regime and a $604M advisory verdict that has already knocked ~18% off the stock. The single most important output from this call may not be the EPS beat — it will be management's framing of financial exposure, insurance coverage, reserves, and appeal path on the verdict, and whether the FY guidance survives intact.

Note: verdict, litigation, and consensus/price-reaction details above are drawn from public news and SEC filings; the specific dollar exposure and any accounting treatment remain unquantified pending the company's own disclosure.